MTM Quality Metrics & Outcome Assessment 2

Question 1

Which CMS quality measure tracks the percentage of Medicare beneficiaries with diabetes who received an ACE inhibitor or ARB?

Accepted Answer

Renin-Angiotensin System Antagonist Use in Diabetic Nephropathy

Answer

The RAS antagonist measure specifically tracks ACE inhibitor or ARB use in diabetic patients to reduce nephropathy progression.

Question 2

In MTM outcome tracking, a 'surrogate endpoint' is best described as:

Accepted Answer

A measurable biomarker expected to predict a clinical outcome

Answer

Surrogate endpoints are biomarkers (e.g., HbA1c, LDL-C) that are reasonably expected to predict true clinical outcomes like hospitalizations or mortality.

Question 3

A pharmacy calculates its Medication Adherence for Hypertension (RAS antagonists) star rating measure. The denominator includes patients who:

Accepted Answer

Were enrolled in Part D for the full measurement year and had a RAS antagonist claim

Answer

The denominator for Part D adherence star measures requires continuous Part D enrollment and evidence of medication use via claims.

Question 4

The 'proportion of days covered' (PDC) is preferred over 'medication possession ratio' (MPR) for adherence measures primarily because:

Accepted Answer

PDC prevents days covered from exceeding 100% by capping at the follow-up period

Answer

PDC caps the numerator at the observation window length, preventing inflation above 100% when patients stockpile refills early.

Question 5

During a quarterly MTM quality review, a pharmacist finds that 30% of enrolled patients have a PDC below 0.80 for their statin. The FIRST action should be to:

Accepted Answer

Conduct targeted medication reviews to identify adherence barriers

Answer

Identifying root causes of non-adherence through targeted reviews allows individualized interventions to improve outcomes.

(MTM) Medication Therapy Management Board Certification Practice Test

(MTM) Medication Therapy Management Board Certification Practice Test

MTM Quality Metrics & Outcome Assessment 2